English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1440]
News [2204]
Articles [39]
Editorials [5]
Conferences [149]
elearning [0]
Pterocarpanquinones and carbapterocarpans with anti-tumour activity against MDR leukaemias
Pterocarpanquinones and carbapterocarpans with anti-tumour activity against MDR leukaemias
Study reveals that many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable to do so
Study reveals that many oncologists recommend medical marijuana clinically despite not feeling sufficiently...
Tracing the footprints of a tumour: Genomic 'scars' allow cancer profiling
Tracing the footprints of a tumour: Genomic 'scars' allow cancer profiling
Generic options provide limited savings for expensive drugs
Generic options provide limited savings for expensive drugs
Drug combination targeting HSP90 and BRAF is safe and effective in advanced melanoma
Drug combination targeting HSP90 and BRAF is safe and effective in advanced melanoma
Discovery adds to evidence that some children are predisposed to develop leukaemia
Discovery adds to evidence that some children are predisposed to develop leukaemia
ESTRO and EORTC announce a new collaboration to maximise the benefits of radiation oncology
ESTRO and EORTC announce a new collaboration to maximise the benefits of radiation oncology
AACR 2018: Pembrolizumab reduced the risk for recurrence of stage 3 melanoma
AACR 2018: Pembrolizumab reduced the risk for recurrence of stage 3 melanoma
Immunotherapy provides long-term survival benefit: Further evidence in lung cancer
Immunotherapy provides long-term survival benefit: Further evidence in lung cancer
Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer
Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer
<1...139140141142143...221>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top